Agius Rudi, Parviz Mehdi, Niemann Carsten Utoft
Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Leuk Lymphoma. 2022 Feb;63(2):265-278. doi: 10.1080/10428194.2021.1973672. Epub 2021 Oct 6.
Artificial intelligence (AI), machine learning and predictive modeling are becoming enabling technologies in many day-to-day applications. Translation of these advances to the patient's bedside for AI assisted interventions is not yet the norm. With specific emphasis on CLL, here, we review the progress of prognostic models in hematology and highlight sources of stagnation that may be limiting significant improvements in prognostication in the near future. We discuss issues related to performance, trust, modeling simplicity, and prognostic marker robustness and find that the major limiting factor in progressing toward state-of-the-art prognostication within the hematological community, is not the lack of able AI algorithms but rather, the lack of their adoption. Current models in CLL still deal with the 'average' patient while the use of patient-centric approaches remains absent. Using lessons from research areas where machine learning has become an enabling technology, we derive recommendations and propose methods for achieving state-of-the-art predictions in modeling health data, that can be readily adopted by the CLL modeling community.
人工智能(AI)、机器学习和预测建模正成为许多日常应用中的使能技术。将这些进展转化为用于人工智能辅助干预的床边患者应用,目前尚未成为常态。在此,特别强调慢性淋巴细胞白血病(CLL),我们回顾血液学中预后模型的进展,并突出可能在近期限制预后显著改善的停滞根源。我们讨论与性能、可信度、建模简易性以及预后标志物稳健性相关的问题,并发现血液学领域迈向最先进预后的主要限制因素,不是缺乏可用的人工智能算法,而是缺乏对其的采用。CLL的当前模型仍针对“普通”患者,而以患者为中心的方法仍未得到应用。借鉴机器学习已成为使能技术的研究领域的经验教训,我们得出建议并提出在健康数据建模中实现最先进预测的方法,这些方法可供CLL建模社区轻松采用。